|
gptkbp:instanceOf
|
malaria vaccine
|
|
gptkbp:alsoKnownAs
|
gptkb:RTS,S
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
|
|
gptkbp:ATCCode
|
J07BX05
|
|
gptkbp:containsAdjuvant
|
gptkb:AS01
|
|
gptkbp:countryOfPilotIntroduction
|
gptkb:Ghana
gptkb:Kenya
gptkb:Malawi
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:developedInPartnershipWith
|
gptkb:PATH_Malaria_Vaccine_Initiative
|
|
gptkbp:doseSchedule
|
four doses
|
|
gptkbp:effect
|
about 30-50% against severe malaria in children
|
|
gptkbp:firstLargeScalePilot
|
2019
|
|
gptkbp:fundedBy
|
gptkb:PATH
gptkb:GSK
gptkb:Bill_&_Melinda_Gates_Foundation
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mosquirix
|
|
gptkbp:indication
|
children
|
|
gptkbp:marketedAs
|
GlaxoSmithKline
|
|
gptkbp:primarySideEffects
|
fever
injection site reactions
seizures (rare)
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
malaria
|
|
gptkbp:targetPathogen
|
gptkb:Plasmodium_falciparum
|
|
gptkbp:type
|
recombinant protein vaccine
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:WHORecommendationYear
|
2021
|
|
gptkbp:bfsParent
|
gptkb:RTS,S/AS01
|
|
gptkbp:bfsLayer
|
5
|